Gilead Sciences presented a strategic outlook at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, emphasizing growth in its HIV prevention and treatment portfolio. The company’s HIV prevention business has expanded to a $4 billion run rate, driven by a mid-teens annual growth rate in the broader market. Sunlenca (lenacapavir), approved at the end of Q2 2023, is projected to generate $1 billion in sales for 2024, with a 70% persistence rate among users. The drug’s success underscores its role as a cornerstone in HIV prevention, alongside its weekly oral and injectable variants expected by 2025 and 2028, respectively.
Gilead Sciences Highlights HIV Pipeline, Market Expansion at Cantor Fitzgerald Conference
Gilead Sciences outlined a robust HIV prevention and treatment strategy, with Sunlenca (lenacapavir) nearing $1 billion in 2024 sales and BIKTARVY dominating U.S. market share at 52%. R&D productivity surged to over 10 molecules annually, while patent cliff risks from TRUVADA are being mitigated through strategic acquisitions and IRA pricing negotiations.
SL
Sophie Laurent · FX & Rates Desk · 21 Sept 2026 · 04:38 · 1 Min. Lesezeit
Dieser Artikel wurde mit KI-Unterstützung erstellt und von einer Finances-Review-Redakteurin bearbeitet.
ADVERTISEMENT
SL
Geschrieben von
Sophie Laurent
FX & Rates Desk
Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.
Mehr von Sophie Laurent →
